Ewopharma and Vianex announce collaboration to distribute the essential antibiotic Amikacin in Switzerland


Schaffhausen, 29 July 2019 – Ewopharma and Vianex S.A. are pleased to announce their new partnership for distribution of Amikacin in Switzerland. Ewopharma will be the new market authorisation holder for the drug and assuming all responsibilities of the former distributor Bristol Myers Squibb.

Amikacin is an aminoglycoside antibiotic used to treat a number of severe bacterial infections. The drug inhibits protein synthesis of sensitive bacteria and is indicated for short-term treatment of severe infections caused by amikacin-sensitive Gram-negative pathogens.
Amikacin is listed as an essential medicine on the WHO model list of essential medicines, highlighting the importance of this drug in the fight against bacterial infections. In line with the WHO’s assessment, the Federal Office of Economic Land Supply (BWL) also requires a compulsory stock for Amikacin.

Ewopharma’s Dr. Friederike Skott, Country Manager Switzerland Ewopharma AG, comments: “We are very happy to be able to ensure the continued availability of this essential antibiotic medicine, especially in the face of current shortages of essential hospital drugs in Switzerland.”
Reto Schaberl, Director Business Development & Specialty Pharma Ewopharma AG, states: “Amikacin fits very well with our strategy to provide relevant niche products for the health systems in our markets.”
Dimitris P. Giannakopoulos, President & CEO of VIANEX S.A. adds: “We are pleased to announce our collaboration with Ewopharma for the distribution of Amikacin in Switzerland. This new partnership confirms that VIANEX continuously enhances its existing network of collaborations. We are confident that it will be a very successful partnership and we guarantee the continuous supply of this product.